Navigation Links
Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
Date:10/20/2010

LONDON, Oct. 20 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") announces that the European Patent Office (EPO) has granted a new patent that provides broad protection on novel aspects of the RNAi structural modification technology known as the "Zamore Design Rules."  European patent number 1 633 890 titled "Methods and Compositions for Enhancing the Efficacy and Specificity of RNAi" was published today in the European Patent Bulletin.  The European patent covers various breakthrough structural modification methods and compositions which Silence believes are fundamental for the development and commercialization of RNAi therapeutics with enhanced efficacy.

"The granting of this comprehensive patent in Europe is a significant milestone for Silence in our ongoing effort to build one of the world's leading RNAi intellectual property positions.  We have consistently built a strong IP estate around the Zamore technology in the U.S. and have now extended our global coverage to Europe with the granting of this critical patent," stated Philip Haworth, Ph.D., chief executive officer of Silence Therapeutics.  "We have often stated our belief that the 'Zamore Design Rules' represent significant IP to enable the process of bringing effective RNAi therapeutics to market.  With this latest patent grant from the EPO, we are excited to be able to offer potential collaborators or licensing partners access to this strongly protected Zamore technology in both the U.S. and Europe."

The issued patent's method and composition claims include:

  • Methods of enhancing the ability of an antisense strand of an RNAi agent to act as a guide strand
  • RNAi or siRNA agents for enhancing silencing of a target mRNA in a subject
  • Compositions for siRNA duplexes include pre-miRNA and shRNA and vectors to perform the methods described herein

Silence owns excl
'/>"/>

SOURCE Silence Therapeutics plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
2. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
3. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
4. Silence Therapeutics Appoints New Vice President of Research
5. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
6. National Ovarian Cancer Coalition and PureOlogy to Host First Annual NOCC and PureOlogys Walk to Break the Silence on Ovarian Cancer
7. Precision Therapeutics President and CEO Sean McDonald Recognized as Pittsburgh Technology Council Tech 50 CEO of the Year
8. Fate Therapeutics Announces Collaboration With BD to Develop and Commercialize Induced Pluripotent Stem Cell Technology
9. Northwest Biotherapeutics to Present at Inaugural Cancer Immunotherapy Conference
10. Orexigen® Therapeutics Announces Upcoming Data Presentations at the 28th Annual Scientific Meeting of The Obesity Society
11. Cell Therapeutics, Inc. (CTI) to Present at 9th Annual BIO Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 27, 2015  CASI Pharmaceuticals, Inc. (Nasdaq: CASI ... and commercialization of innovative therapeutics addressing cancer and other ... commercial focus on China , today ... ended December 31, 2014.  The Company ... per share, for the three months ended December 31, ...
(Date:3/26/2015)... (PRWEB) March 26, 2015 PRC Clinical, ... announced today several management and executive appointments effective immediately. ... Financial Officer (CFO) and member of the Board of ... Business Operations, and Sue Dowden will assume the position ... and current Chief Operations Officer (COO), has been appointed ...
(Date:3/26/2015)...  BioNano Genomics, Inc., the leader in genome mapping, ... chief commercial officer. Salyer has more than 20 years ... life sciences. At BioNano, Salyer will oversee the commercialization ... to assemble a comprehensive view of complex genomes to ... institutions located in the United States ...
(Date:3/26/2015)... March 26, 2015 PAREXEL International ... clinical research organization , announced today ... agreement to acquire all of the business ... leading provider of specialized pharmacovigilance services, based ... collection, detection, assessment, monitoring, and prevention of ...
Breaking Biology Technology:CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 4CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 5CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 6PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 2PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 3BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 2BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 4
... Mass., Nov. 9, 2010 Boston Scientific Corporation (NYSE: ... of its Vercise™ Deep Brain Stimulation (DBS) System as ... multi-center, prospective trial designed to examine the improvement of ... the Vercise DBS System for the treatment of Parkinson,s ...
... novel, real-time imaging system, scientists have tracked a group ... lungs, into the body and out again, providing a ... particles which could be used in developing therapeutic agents ... greater understanding of the health effects of air pollution. ...
... (Nasdaq: KNDL ), a leading, global full-service ... the third quarter of 2010 of $131.4 million. Contract ... to $10.4 million or 1.3 percent of the Company,s ... book-to-bill of 1.5. New business authorizations (backlog) at Sept. ...
Cached Biology Technology:Boston Scientific Begins Patient Enrollment in Clinical Trial Assessing Deep Brain Stimulation for Parkinson's Disease 2Boston Scientific Begins Patient Enrollment in Clinical Trial Assessing Deep Brain Stimulation for Parkinson's Disease 3Boston Scientific Begins Patient Enrollment in Clinical Trial Assessing Deep Brain Stimulation for Parkinson's Disease 4Scientist chronicle nanoparticles' journey from the lungs into the body 2Scientist chronicle nanoparticles' journey from the lungs into the body 3Kendle Announces Third Quarter 2010 Results 2Kendle Announces Third Quarter 2010 Results 3Kendle Announces Third Quarter 2010 Results 4Kendle Announces Third Quarter 2010 Results 5Kendle Announces Third Quarter 2010 Results 6
(Date:3/5/2015)... 5, 2015 In Brazil , ... already using these solutions and 42 percent planning to invest ... approximately 25 percent of the companies will be investing in ... majority of companies in the region are currently opting for ... model will command significant attention in the coming years. This ...
(Date:3/2/2015)... March 2, 2015 Synaptics Inc. (NASDAQ: ... human interface solutions, today announced a new implementation ... to enable rapid and secure transactions and reliable ... gaming is a turnkey solution providing mouse and ... quickly integrate fingerprint ID solutions into their product ...
(Date:2/25/2015)... , Feb. 25, 2015  ABC Financial Services ... in the Health and Fitness Industry, today announced ... to MYiCLUBonline.  The latest upgrade includes advances to ... of cardless check-in via Identity One fingerprint biometrics. ... time through interactive displays at the International Health, ...
Breaking Biology News(10 mins):Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3
... 2011 Based on its recent analysis of ... recognizes Cardiocom with the 2011 North American Frost ... integrated clinical telehealth services that offer significant cost ...   http://photos.prnewswire.com/prnh/20081117/FSLOGO ) Cardiocom combines advanced ...
... Inexpensive igloo-shaped, pollution-eating devices nicknamed "Poo-Gloos" can ... treatment facilities for towns outgrowing their waste-treatment lagoons, ... results of this study show that it is ... hundreds of thousands, if not millions of dollars, ...
... rethinking what happens on the surface of things, engineers ... biofilm colonies exhibit an unmatched ability to repel ... across yet only hundreds of microns thick, such slimy ... pipes to teeth and are notoriously resistant to antimicrobial ...
Cached Biology News:Frost & Sullivan Recognizes Cardiocom as a Technology Enabler for Superior Cost-Effective Remote Chronic Care Management 2Frost & Sullivan Recognizes Cardiocom as a Technology Enabler for Superior Cost-Effective Remote Chronic Care Management 3Frost & Sullivan Recognizes Cardiocom as a Technology Enabler for Superior Cost-Effective Remote Chronic Care Management 4Igloo-shaped 'Poo-Gloos' eat sewage 2Igloo-shaped 'Poo-Gloos' eat sewage 3Igloo-shaped 'Poo-Gloos' eat sewage 4Igloo-shaped 'Poo-Gloos' eat sewage 5A pesky bacterial slime reveals its survival secrets 2A pesky bacterial slime reveals its survival secrets 3
... cDNA normalization is essential for ... using high-throughput approaches, such as EST ... Most normalization methods are not well ... cDNA. The Evrogen TRIMMER kit, though, ...
... Tecan has 20 years of expertise ... (ELISA), and still offers the most powerful ... manages up to 40 000 in-microplate tests ... The integration of different modules (such as ...
... 6 delivers enhanced statistics and statistical ... quality improvement managers. As an accepted ... 6 simplifies statistics for novice users ... by experts. It offers a powerful ...
Glycerol-based mounting medium for immunofluorescence microscopy. Formulated to retard photobleaching of fluorochromes such as fluorescein and rhodamine. Product can also be used as a diluent for fl...
Biology Products: